News tagged with 'Rosiglitazone'

Food and Drug Administration advisers voted 14-2, that all new diabetes drugs should undergo longer cardiovascular trials to assure they don't increase the risk of heart related problems.

The FDA Chooses Avandia Over Patients Updated August 2007: The FDA has known of the risk of heart failure associated with Avandia , a type 2 diabetes medicine, for years. Even before the drug was approved, researchers mentioned that there was a risk of cardiovascular illness. But the

Avandia to Stay, says FDA Panel Updated August 2007: A federal drug advisory committee voted 22 to 1 on July 30 that GlaxoSmithKline’s Avandia should remain on the market; although the committee also voted 20 to 3 that the diabetes drug raises the risk of heart attack. Committee members de

July 30 th FDA Meeting to Discuss Avandia Updated July 2007: On July 30, 2007, the FDA will meet with GlaxoSmithKline to discuss the diabetes drug Avandia . The fact-gathering meeting is intended to thrash out the issue of increased heart attack risk for users from the drug. The FDA

Older Diabetes Drugs Work as Well as Avandia Older, cheaper diabetes drugs appear to work as well as Avandia, resolved an analysis on the efficacy of metformin and Avandia , which has recently come under close scrutiny for its ties to heart problems. Between the two, the clear winner is

Updated June, 2007: At the American Diabetes Association ’s annual meeting in Chicago, experts on Avandia debated recent findings about the drug from a study published in the New England Journal of Medicine. The findings show that Avandia users have a 43% increased risk for heart attacks and

Avandia Warnings Ignored by FDA Avandia , a drug for patients with diabetes, was approved on May 25, 1999. The drug was approved because it was shown to be effective in reducing blood sugar levels. Even before the drug was approved, however, there were warnings that revealed that the drug may increase the